A drug commonly used to induce medical abortions may hold new promise for high-risk breast cancer women, say an international team of physicians and researchers. Mifepristone, the drug, has shown to impede the development of cancer cells, but stigma over its link to abortion is said to be stifling important research.
Mifepristone, often used in combination with misoprostol for abortion through ten weeks, has been demonstrated in three independent studies released in 2008, 2022, and 2024 to constrain the action of progesterone, a hormone that stimulates the growth of breast cancer cells. Despite all of this, drug companies have refused to pursue additional research.
Specialists are contending that social and political debate over abortion limits the investigation of mifepristone’s broader uses in medicine. “It is profoundly disappointing that mifepristone’s success in a single medical field is blocking research with the potential to greatly improve public health,” wrote authors of a recent opinion article in The Lancet Obstetrics, Gynaecology and Women’s Health. The piece was authored by eight doctors of reproductive health and cancer in London, Edinburgh, Stockholm, and Erbil, Iraq.
Possible Life-Saving Advantage to High-Risk Women
If effective, mifepristone would provide a non-surgical alternative to women who are genetically at risk for breast cancer, including those who have BRCA1 or BRCA2 mutations. Such women currently have high-risk strategies such as mastectomies or medication that is not very effective.
Dr. Simon Vincent, Breast Cancer Now’s chief scientific officer, underlined the pressing need for additional choices. “High-risk women need treatments that ensure their quality of life. Investigating drugs already out there such as mifepristone might be a vital option,” he said.
Initial studies indicate that even short, low-dose courses of mifepristone taking two to three months can retard runaway growth in breast tissue. Dr. Marianne Baker of Cancer Research UK also said that, with almost 58,000 new cases of breast cancer being diagnosed in Britain annually, it is essential to investigate preventive therapy. “Scientists need to find out if mifepristone works, how it works, and in whom it works best,” she said.
Calls for Policy and Research Support
The Lancet authors call on governments to loosen controls on mifepristone so that it can be examined in its entirety by researchers. Prof. Kristina Gemzell Danielsson, leader of women’s and children’s health at Sweden’s Karolinska Institute in Stockholm, added that stigma about abortion is a major hindrance. “Our data support the prevention of aggressive breast cancer using mifepristone. All studies were randomized controlled trials safely using low doses,” she said.
UK cancer charities have joined the appeal, calling on drug firms and policymakers to make research into mifepristone as a preventative treatment a priority. The hope is that bypassing regulatory and social barriers could release a life-saving treatment for millions of women across the globe.
As investigators insist on trials and the public demands more, mifepristone could soon come into prominence not only as an abortifacient but possibly as a weapon in the battle against one of the world’s most prevalent and lethal malignancies.
ALSO READ: Artificial Sweetener Sucralose May Hamper Cancer Immunotherapy, Says New Study
